If you have been reading about Cyclic AMP and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-29. Numbers and descriptions here follow the published literature rather than marketing material.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Other GABAA receptor positive allosteric modulators with hypnotic effects include alcohol (ethanol), chloral hydrate, urethane (ethyl carbamate), isoflurane, allopregnanolone (brexanolone), and propofol, among others.
==== Coupling with separation techniques ==== DART can be combined with many separation techniques. Thin-layer chromatography (TLC) plates have been analyzed by positioning them directly in the DART gas stream. Gas chromatography has been carried out by coupling gas chromatography columns directly into the DART gas stream through a heated interface. Eluate from a high-pressure liquid chromatograph (HPLC) can be also introduced to the reaction zone of the DART source and analyze. DART can be coupled with capillary electrophoresis (CE) and the eluate of CE is guided to the mass spectrometer through the DART ion source.
Quinupristin/dalfopristin, or quinupristin-dalfopristin, (pronunciation: kwi NYOO pris tin / dal FOE pris tin) (trade name Synercid) is a combination of two antibiotics used to treat infections caused by staphylococci and by vancomycin-resistant Enterococcus faecium. Quinupristin and dalfopristin are both streptogramin antibiotics, derived from pristinamycin. Quinupristin is derived from pristinamycin IA; dalfopristin from pristinamycin IIA. They are combined in a weight-to-weight ratio of 30% quinupristin to 70% dalfopristin. Discontinued 2022, there are no other manufacturers of this medication.
Helium–cadmium lasers are a common source of blue or ultraviolet laser light. Lasers at wavelengths of 325, 354 and 442 nm are made using this gain medium; some models can switch between these wavelengths. They are notably used in fluorescence microscopy as well as various laboratory uses requiring laser light at these wavelengths.
Transitional epithelium, also known as urothelium is a type of stratified epithelium that changes shape in response to stretching.. Transitional epithelium usually appears cuboidal when relaxed and squamous when stretched. This tissue consists of multiple layers of epithelial cells which can contract and expand in order to adapt to the degree of distension needed. Transitional epithelium lines all of the organs of the urinary system – the kidneys, ureters, bladder, and the urethra, hence its alternative name of urothelium. The bladder, for example, has a need for great distension.
Sources: en.wikipedia.org
== Contraindications == Somapacitan should not be used in people with active malignancy, any stage of diabetic eye disease in which high blood sugar levels cause damage to blood vessels in the retina, acute critical illness, or those with acute respiratory failure, because of the increased risk of mortality with use of pharmacologic doses of somapacitan in critically ill individuals without growth hormone deficiency.
The traditions of British centenarians receiving greetings and congratulations was established by King Edward VII in 1908. The famous acrobat and tightrope walker Henry Johnson received a congratulatory letter from Edward VII via his royal courtier Viscount Knollys in 1906. The tradition of royal congratulations continued in 1908, when the secretary for King Edward VII sent a congratulatory letter to Reverend Thomas Lord of Horncastle, Lincolnshire, in a newspaper clipping, declaring, "I am commanded by the King to congratulate you on the attainment of your hundredth year, after a most useful life." The practice was formalised from 1917, under the reign of King George V, who also sent congratulations then sent by a telegram on the attainment of a diamond wedding anniversary (or jubilee) marking 60 years of marriage. During the reign of King George V, only 24 telegrams were sent; however, with the aging population, this increased to 273 during 1952, when Queen Elizabeth II ascended the throne. The Queen also sent a telegram, and later a portrait-style greeting card with the notation, "I am so pleased to know that you are celebrating your one hundredth birthday. I send my congratulations and best wishes to you on such a special occasion." Each few years the card was updated with a current updated picture of the Queen to ensure people did not receive the same card more than once. The Queen further sent her congratulations on one's 105th birthday and every year thereafter as well as on special wedding anniversaries.
=== Pharmacokinetics === Detailed pharmacokinetic studies on arsenic trioxide have not been conducted. When administered intravenously, a steady state is reached after 8–10 days. Arsenic binds to proteins to an insignificant extent. The highest concentrations of arsenic are found in the liver, kidneys, heart, lungs, hair, and nails. Arsenous acid is oxidized to arsenic acid and methylated in the liver, and then excreted 60% in the urine. The drug has a half-life of 92 hours. Arsenic trioxide is neither a substrate nor an inhibitor of cytochrome P450 isozymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, 4A9/11).
The Kizil Caves were first discovered and explored in 1902–1904 by the Ōtani expedition, a Japanese expedition under Tesshin Watanabe (渡辺哲信) and Kenyu Hori (堀賢雄), funded by Count Otani, but the expedition left hurriedly after four months of exploration in the area of Kucha, following a local earthquake. The Kizil caves were then explored by Albert Grünwedel, head of the Third German Turfan Expedition (December 1905 – July 6, 1907). Albert von Le Coq was also part of the third German expedition and was under the direction of Albert Grünwedel, but only remained until June 1906, when he had to leave for British India due to a heavy illness. The caves were photographed, drawings were made, and large portions of the murals were removed and sent to Germany. Grünwedel removed a great number of paintings, but was careful to make records before doing so in order to retain their archaeological value, and to photograph or draw them before cutting them out, out of fear that they could be destroyed upon removal or during transport. He used a canvas to take quite precise records of the paintings. For example, Grünwedel recounts how he discovered a very interesting mural with warriors in the Cave of the Painters (207). Intending to remove it, he first made a precise drawing. But once the drawing was made, the mural disintegrated upon removal and was lost, except for a few fragments still in-situ. Altogether, the Third German Expedition still removed many paintings, and shipped almost 120 crates of murals to Berlin.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.